ISPOR - CO39 Real-World Assessment of Efficacy and Safety of Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: Systematic Review and Meta-Analysis

CO39 Real-World Assessment of Efficacy and Safety of Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: Systematic Review and Meta-Analysis

Abstract

Authors

Z. Almalki

Full Text Cite This Article

Back to Volume 26, Supplemental Issue 6S

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now